Macrophages and dendritic cells as actors in the immune reaction of classical hodgkin lymphoma

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Tudor, Christiane Silke ^a   Bruns, Heiko ^a   Daniel, Christoph ^a   Distel, Luitpold Valentin ^a   Hartmann, Arndt ^a   Gerbitz, Armin ^a   Buettner, Maike Julia ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRDU ASSAY; CD163+ MONOCYTE; CD83+ MYELOID DENTRITIC CELL; CELL COUNT; CELL INFILTRATION; CELL MATURATION; CELL PROLIFERATION; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SPECIFIC SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; LYMPHOMA CELL LINE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD DERIVED MONOCYTE; POLARIZATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUPERNATANT; TUMOR IMMUNITY; ADOLESCENT; CELLULAR IMMUNITY; HODGKIN DISEASE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNITY, CELLULAR; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84958802672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114345     Document Type: Article

References (65)

1. Gottfried E, Kreutz M, Mackensen A (2008) Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 19: 65-77.
2. Kim R, Emi M, Tanabe K, Arihiro K (2007) Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121: 149-157.
3. Demoulin S, Herfs M, Delvenne P, Hubert P (2013) Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 93: 343-352.
4. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
5. Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224-2234.
6. Yung L, Linch D (2003) Hodgkin's lymphoma. Lancet 361: 943-951.
7. Steidl C, Connors JM, Gascoyne RD (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29: 1812-1826.
8. Barros MH, Hassan R, Niedobitek G (2012) Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: Association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 18: 3762-3771.
9. Benharroch D, Guterman G, Levy I, Shaco-Levy R (2010) High content of Langerhans cells in malignant lymphoma-incidence and significance. Virchows Arch 457: 63-67.
10. Abdou AG, Asaad NY, Loay I, Shabaan M, Badr N (2013) The prognostic role of tumor-associated macrophages and dendritic cells in classic Hodgkin's lymphoma. J Environ Pathol Toxicol Oncol 32: 289-305.
11. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4: 941-952.
12. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, et al. (2003) Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104: 92-97.
13. Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, et al. (2003) Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 10: 1237-1240.
14. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, et al. (2002) The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8: 3480-3486.
15. Steidl C, Lee T, Shah SP, Farinha P, Han G, et al. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-885.
16. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, et al. (2005) Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175: 342- 349.
17. Sica A, Larghi P, Mancino A, Rubino L, Porta C, et al. (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18: 349-355.
18. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
19. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290.
20. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
21. Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9: 177.
22. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, et al. (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164: 762-767.
23. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
24. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
25. Coppleson LW, Rappaport H, Strum SB, Rose J (1973) Analysis of the Rye classification of Hodgkin's disease. The prognostic significance of cellular composition. J Natl Cancer Inst 51: 379-390.
26. Ree HJ, Kadin ME (1985) Macrophage-histiocytes in Hodgkin's disease. The relation of peanutagglutinin- binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer 56: 333-338.
27. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, et al. (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 96: 269-276.
28. Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, et al. (2012) CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 88: 292-305.
29. Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, et al. (2011) Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 459: 361-366.
30. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, et al. (2012) Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood 120: 3280-3287.
31. Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180: 2011-2017.
32. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Medeiros LJ, Vega F, et al. (2012) Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 97: 1080-1084.
33. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, et al. (2012) Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 23: 736-742.
34. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, et al. (2012) CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 7: 12.
35. Tudor CS, Distel LV, Eckhardt J, Hartmann A, Niedobitek G, et al. (2013) B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum Pathol 44: 2475-2486.
36. Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, et al. (2009) RNA extraction from archival formalin-fixed paraffin-embedded tissue: A comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 55: 1719-1727.
37. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, et al. (2004) Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 101: 4560-4565.
38. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135-141.
39. Coventry BJ, Lee PL, Gibbs D, Hart DN (2002) Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 86: 546-551.
40. Coventry BJ, Morton J (2003) CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer 89: 533-538.
41. Zhou LJ, Tedder TF (1995) Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154: 3821-3835.
42. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, et al. (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113: 2765-3775.
43. Ishii H, Takahara M, Nagato T, Kis LL, Nagy N, et al. (2012) Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer 130: 48-58.
44. Jones K, Vari F, Keane C, Crooks P, Nourse JP, et al. (2013) Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 19: 731-742.
45. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, et al. (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99: 618-626.
46. Brower V (2005) Researchers attempting to define role of cytokines in cancer risk. J Natl Cancer Inst 97: 1175-1177.
47. Dinarello CA (2006) The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 25: 307-313.
48. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, et al. (2014) Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40: 274-288.
49. Akila P, Prashant V, Suma MN, Prashant SN, Chaitra TR (2012) CD163 and its expanding functional repertoire. Clin Chim Acta 413: 669-674.
50. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, et al. (2011) Tumorassociated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 55: 861- 867.
51. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, et al. (1996) Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87: 3418-3428.
52. Klein S, Jucker M, Diehl V, Tesch H (1992) Production of multiple cytokines by Hodgkin's disease derived cell lines. Hematol Oncol 10: 319-329.
53. Natoli A, Lupertz R, Merz C, Muller WW, Kohler R, et al. (2013) Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer 133: 1945-1954.
54. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, et al. (1999) Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189: 1939-1946.
55. Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, et al. (1990) Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res 50: 2049-2055.
56. Hsu PL, Lin YC, Hsu SM (1991) Expression of macrophage colony-stimulating factor (M-CSF) in two Hodgkin's Reed-Sternberg (H-RS) cell lines, HDLM-1 and KM-H2, and in H-RS cells in tissues. Int J Hematol 54: 315-326.
57. Dufresne M, Dumas G, Asselin E, Carrier C, Pouliot M, et al. (2011) Pro-inflammatory type-1 and antiinflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells. Mol Immunol 48: 1556-1567.
58. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, et al. (1986) Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506-508.
59. Williams MA, Newland AC, Kelsey SM (1997) Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Br J Haematol 98: 960-968.
60. Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ, et al. (2002) Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 168: 1823-1830.
61. Vanderheyde N, Vandenabeele P, Goldman M, Willems F (2004) Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunol Lett 91: 99-101.
62. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, et al. (2002) Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168: 1831-1839.
63. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, et al. (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189: 1343-1354.
64. Reed SG, Nathan CF, Pihl DL, Rodricks P, Shanebeck K, et al. (1987) Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med 166: 1734-1746.
65. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, et al. (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14: 425-431.